AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24521993
Drug: Subcutaneous rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous rituximab (1400 mg)
Trial: 19512978
Drug: Aripiprazole 15
RxNorm normalized name: aripiprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 15 mg/d
Trial: 8511923
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) with PMUE therapy: cisplatin (CDDP) 75 mg/m2, mitomycin C (MMC) 10 mg/body, etoposide 150 mg/body, and UFT 400 mg/day.
Trial: 8511923
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (surgery first, then PMUE therapy).
Trial: 8511923
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) group.
Trial: 30402206
Drug: High vegetable
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High vegetable consumption (4200 g of vegetables/week)
Trial: 30402206
Drug: Low vegetable
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low vegetable consumption (800 g of vegetables/week)
Trial: 22875224
Drug: Vacuum‐assisted closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum‐assisted closure (VAC) therapy
Trial: 15883427
Drug: Low dietary
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dietary zinc intake (3.8 mg/d)
Trial: 15883427
Drug: Supplemented zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemented zinc intake (18.7 mg/d)
Trial: 12452732
Drug: Liposomal formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal formulation of anthracyclines
Trial: 12452732
Drug: Cardioprotective agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioprotective agents
Trial: 12452732
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of anthracyclines
Trial: 12452732
Drug: Timed sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timed sequential therapy
Trial: 7740949
Drug: Parenteral cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral cefuroxime
Trial: 7069203
Drug: UVA treatment
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVA treatment
Trial: 7069203
Drug: 8‐methoxypsoralen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8‐methoxypsoralen treatment
Trial: 22536131
Drug: Interferon-gamma (IFN-γ)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-gamma (IFN-γ) 50 μg/m² subcutaneously three times per week (n = 20)
Trial: 22536131
Drug: Topical betamethasone
RxNorm normalized name: betamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betamethasone valerate 0.1% cream every night for 30 days (n = 20)
Trial: 19696126
Drug: Self-administered computerized
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered computerized versions of the baseline dyspnea index
Trial: 17521397
Drug: Tegaserod 6
RxNorm normalized name: tegaserod 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 6 mg b.i.d (12 patients)
Trial: 17521397
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (10 patients)
Trial: 15203296
Drug: Fluoxetine or
RxNorm normalized name: fluoxetine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine or Paroxetine (active medication)
Trial: 11380322
Drug: LCM-7 (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCM-7 (lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg twice daily for 7 days)
Trial: 11380322
Drug: LCMB-3 (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCMB-3 (lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg, bismuth subcitrate 240 mg twice daily for 3 days)
Trial: 8062489
Drug: Probenecid (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probenecid (2 gm) with adinazolam (60 mg)
Trial: 8062489
Drug: Adinazolam (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adinazolam (60 mg)
Trial: 2839025
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Calcium and 25 micrograms cholecalciferol per day
Trial: 29310711
Drug: Collaborative pharmaceutical
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Collaborative pharmaceutical care with medication reconciliation and review performed by a clinical pharmacist during the experimental period
Trial: 29310711
Drug: Collaborative pharmaceutical
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Collaborative pharmaceutical care
Trial: 16015413
Drug: Argatroban (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban (median doses: 1.5‐2.0 mcg/kg/min)
Trial: 16015413
Drug: Cotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotherapy with Argatroban and Warfarin (median dose: 5 mg initially with 3.8 mg/day thereafter)
Trial: 16015413
Drug: Cotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotherapy with Argatroban and Warfarin
Trial: 15259476
Drug: 14-day primaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day primaquine regimen (15 mg/d)
Trial: 15259476
Drug: No antirelapse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antirelapse therapy
Trial: 10997897
Drug: Mifepristone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (200 mg) + vaginal meteneprost (5 mg)
Trial: 10997897
Drug: Mifepristone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (200 mg) + oral misoprostol (600 microg)
Trial: 31309857
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (LT)
Trial: 31728510
Drug: Early intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intervention with anti-TNF-α treatment
Trial: 31728510
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (steroids and/or immunomodulators)
Trial: 27509063
Drug: Cetuximab (EGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (EGFR inhibitor)
Trial: 20858862
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg daily) concomitantly with clopidogrel
Trial: 20858862
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg daily) staggered by 8 to 12 hours with clopidogrel
Trial: 17600281
Drug: Thymosin alpha
RxNorm normalized name: Thymosin alpha 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin alpha 1 (Talpha1) as an adjunct to influenza vaccination
Trial: 15603047
Drug: Parenteral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral antibiotics (metronidazole and cefoxitin)
Trial: 9871432
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (controlled by feedback, twice daily)
Trial: 9871432
Drug: Usual doses
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual doses of cyclosporine and corticosteroids
Trial: 7639018
Drug: vaccine +
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaccine + low-dose DETOX (10 micrograms MPL + 100 micrograms CWS)
Trial: 7639018
Drug: vaccine +
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaccine + high-dose DETOX (20 micrograms MPL + 200 micrograms CWS)
Trial: 7639018
Drug: vaccine +
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaccine + alum (control group)
Trial: 7639018
Drug: DETOX group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DETOX group (combined low and high dose)
Trial: 1695304
Drug: Isradipine 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 1.25 mg b.i.d.
Trial: 1695304
Drug: Isradipine 2.5
RxNorm normalized name: isradipine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 2.5 mg b.i.d.
Trial: 365541
Drug: Ordinary lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary lithium carbonate (1.80 g = 24.3 mmol)
Trial: 365541
Drug: Sustained-release lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release lithium carbonate (1.80 g = 24.3 mmol)
Trial: 365541
Drug: Healthy volunteers
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers (ordinary preparation)
Trial: 365541
Drug: Manic subjects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manic subjects (sustained-release preparation)
Trial: 29062324
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A (5000 IU) and Vitamin C (2600 mg) supplementation for 1 month
Trial: 21628364
Drug: Weekly vitamin
RxNorm normalized name: Ezy Dose Weekly Vitamin Planner 2XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly vitamin D supplements (35 µg/week) for six months
Trial: 16966109
Drug: Antibiotics (clindamycin-gentamycin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (clindamycin-gentamycin)
Trial: 11423708
Drug: Nitrate withdrawal
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate withdrawal (40 mg isosorbide dinitrate twice daily)
Trial: 3780125
Drug: SQ 28,668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ 28,668 (doses ranging from 25 to 1200 mg)
Trial: 22425129
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity extracorporeal shock wave therapy
Trial: 20110563
Drug: Single retinyl
RxNorm normalized name: RETINYL PALMITATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single retinyl palmitate dose of 200,000 IU (S1)
Trial: 20110563
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of retinyl palmitate 200,000 IU 24 hours apart (S2)
Trial: 12810415
Drug: Grilled spinach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grilled spinach with sour cream
Trial: 19853906
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg
Trial: 8350584
Drug: Prophylactic vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic vancomycin (10 mg/kg/day in two doses)
Trial: 8350584
Drug: Vancomycin plus
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin plus oral cefixime for patients with positive cultures for gram-negative organisms
Trial: 3001520
Drug: vidarabine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vidarabine (15 mg/kg/day for 10 days)
Trial: 3001520
Drug: acyclovir (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acyclovir (30 mg/kg/day for 10 days)
Trial: 29622512
Drug: Heparin coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin coated grafts
Trial: 12639494
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of inactivated poliovirus vaccine (IPV) at 6, 10, and 14 weeks together with oral poliovirus vaccine (OPV)
Trial: 12639494
Drug: One additional
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One additional dose of IPV at 14 weeks together with the last dose of OPV
Trial: 8773088
Drug: Prednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (40 mg daily for 2 weeks and then tapered off)
Trial: 23995520
Drug: Sunscreen milk
RxNorm normalized name: ZINC OXIDE 12 g in 100 mL TOPICAL LOTION [GUARDIAN ANGEL SUPER PEPTIDE SUNSCREEN MILK SPF-50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreen milk formulation
Trial: 23995520
Drug: Sunscreen gel
RxNorm normalized name: AVOBENZONE 3 mg in 100 mg / HOMOSALATE 9.5 mg in 100 mg / OCTISALATE 5 mg in 100 mg TOPICAL LOTION [NEORA Invisibloc Sunscreen Gel Broad Spectrum SPF40]
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sunscreen gel formulation
Trial: 18625073
Drug: Combination botanical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination botanical product (CBP) 2 tablets three times a day
Trial: 18625073
Drug: Loratadine 10
RxNorm normalized name: loratadine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine 10 mg once a day
Trial: 18625073
Drug: Combination botanical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination botanical product (CBP)
Trial: 18625073
Drug: None of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: None of the treatments
Trial: 7573999
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion (50 micrograms.kg‐1.min‐1)
Trial: 7572495
Drug: Triple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple dose (0.3 mmol/kg) of gadoteridol
Trial: 7572495
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (0.1 mmol/kg) of gadoteridol
Trial: 30823449
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg once a day (OD)
Trial: 30823449
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg twice a day (BID)
Trial: 28162215
Drug: Multimodal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesia (40 mg parecoxib sodium IV before anesthetic induction, 0.375% ropivacaine 150 mg with dexamethasone 5 mg for transversus abdominis plane block)
Trial: 25835348
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (Prevacid; 30 mg)
Trial: 20023244
Drug: Standard dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dressing without healing promoting agent
Trial: 15585901
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with ADHD on medication
Trial: 15585901
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with ADHD without medication
Trial: 9425640
Drug: levodropropizine syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodropropizine syrup (60 mg t.i.d. for 5 days)
Trial: 9425640
Drug: dextromethorphan syrup
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dextromethorphan syrup (15 mg t.i.d. for 5 days)
Trial: 3318431
Drug: Nabumetone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone (2 g daily)
Trial: 3318431
Drug: Naproxen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (1 g daily)
Trial: 25743367
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training (3x weekly)
Trial: 23249842
Drug: Grass silage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grass silage supplemented with 4 kg concentrate daily
Trial: 23249842
Drug: Grass silage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grass silage supplemented with 8 kg concentrate daily
Trial: 23249842
Drug: Maize silage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maize silage (DM 217 g/kg) as sole forage supplemented with 4 kg concentrate daily
Trial: 23249842
Drug: Maize silage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maize silage (DM 304 g/kg) as sole forage supplemented with 4 kg concentrate daily
Trial: 23249842
Drug: Maize silage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maize silage (DM 217 g/kg) offered as 0.5 of the forage component of the diet supplemented with 4 kg concentrate daily
Trial: 23249842
Drug: Maize silage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maize silage (DM 304 g/kg) offered as 1.0 of the forage component of the diet supplemented with 4 kg concentrate daily
Trial: 20890207
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol (1 g every 6 h)
Trial: 20890207
Drug: Dipyrone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone (1 g every 6 h)
Trial: 20890207
Drug: Parecoxib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parecoxib (40 mg every 12 h)
Trial: 12452232
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine titration in the PACU
Trial: 12452232
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine on demand every 6 hours
Trial: 9053973
Drug: Indomethacin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (25 mg three times a day for 7 days)
Trial: 9053973
Drug: Indomethacin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (25 mg three times a day for 7 days) + Misoprostol (200 micrograms every 6 hours for 7 days)
Trial: 1791771
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oestradiol valerate plus 0.25 mg norgestrel (Cyclabil)
Trial: 1791771
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oestradiol valerate plus 7.5 mg megestrol acetate (EV + MA)
Trial: 7043657
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg sulprostone four hourly with laminaria
Trial: 7043657
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg sulprostone four hourly without laminaria
Trial: 7043657
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg sulprostone eight hourly with laminaria
Trial: 7043657
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg sulprostone eight hourly without laminaria
Trial: 25989381
Drug: Silver Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver Cap (medical topical treatment device)
Trial: 25989381
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care for nipple fissure treatment (control group)
Trial: 24030410
Drug: Full prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full prescription coverage
Trial: 22080794
Drug: Usual prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual prescription coverage
Trial: 17014513
Drug: Surveillance swab
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surveillance swab cultures (Ssc) with topical therapy based on Ssc results (Group A)
Trial: 1536666
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Auranofin and Methotrexate
Trial: 31185083
Drug: Index of
RxNorm normalized name: gr pol-orc/sw ver/rye/Kent/tim 100 index of reactivity SUBLINGUAL TABLET, SUBLINGUAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Index of Orthodontic Treatment Need (IOTN) - Dental Health Component (DHC)
Trial: 31185083
Drug: Index of
RxNorm normalized name: gr pol-orc/sw ver/rye/Kent/tim 100 index of reactivity SUBLINGUAL TABLET, SUBLINGUAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Index of Orthodontic Treatment Need (IOTN) - Aesthetic Component (AC)
Trial: 31185083
Drug: Combined Index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Index of Orthodontic Treatment Need (CIOTN)
Trial: 23643112
Drug: Moderate intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate intensity exercise programme including depression awareness training for care-home staff and 45 min physiotherapist-led group exercise sessions delivered twice weekly.
Trial: 20626146
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with blood-letting therapy
Trial: 18975346
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol 200 mg plus MTX
Trial: 18975346
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol 400 mg plus MTX
Trial: 20155996
Drug: Hypericum perforatum
RxNorm normalized name: Hypericum perforatum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum perforatum 900 mg/day